(HRQoL). [2] [3] [4] Specifically, comorbid CRS was associated with higher frequency of asthma exacerbations in an analysis of data from the National Heart, Lung, and Blood Institute's Severe Asthma Research Program-3. 2 Comorbid CRS has been linked to lower HRQoL, as measured by the Mini Asthma Quality of Life Questionnaire (mini-AQLQ) and the Euro Quality of Life health questionnaire, compared with patients with asthma but no CRS. 4 Type 2 cytokines, specifically IL-4, IL-5, and IL-13, are known to play important roles in the pathogenesis of CRS with nasal polyps (NP) and atopic asthma, [5] [6] [7] which represent type 2mediated mucosal inflammation of the upper and lower airways, respectively. 8 CRS without NP has also been associated with type 2 inflammation in a subset of patients. 9 Dupilumab is a fully human, VelocImmune-derived 10, 11 monoclonal antibody that blocks the shared receptor component of IL-4 and IL-13, thus inhibiting signaling of both IL-4 and IL-13, key drivers of type 2 inflammatory diseases such as atopic dermatitis, asthma, allergic rhinitis, and food allergies. 12 Dupilumab is approved by the US Food and Drug Administration 13 as an add-on maintenance treatment in patients with moderate-tosevere asthma aged !12 years with an eosinophilic phenotype or with oral corticosteroidedependent asthma. Dupilumab is approved in Japan for patients aged !12 years with severe or refractory bronchial asthma whose symptoms are inadequately controlled with existing therapies, 14 and by the European Medicines Agency 15 as an add-on maintenance treatment in patients aged !12 years with type 2 severe asthma characterized by increased blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequately controlled with high-dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment. [16] [17] [18] Dupilumab is approved in the USA as an add-on treatment in patients with inadequately controlled CRS with NP, 13 and adults in the European Union 15 and other countries. [19] [20] [21] In the phase 3 LIBERTY ASTHMA QUEST study, dupilumab reduced severe asthma exacerbations and showed a rapid and sustained improvement in lung function in patients with uncontrolled, moderate-to-severe asthma, with greater treatment effects observed in patients with elevated baseline levels of blood eosinophils or FeNO. 17 In a phase 2a trial in patients with severe CRS with NP refractory to intranasal corticosteroids, dupilumab significantly reduced polyp size and sinus opacification/inflammation, improved nasal congestion, nasal peak inspiratory flow, sense of smell, and HRQoL, and improved asthma control and lung function in a subset of patients with comorbid asthma. 22 These findings were confirmed in 2 phase 3, placebo-controlled studies of dupilumab in patients with severe CRS and NP refractory to systemic corticosteroids and/or surgery (NCT02912468, NCT02898454). After 24 weeks, dupilumab significantly improved NP size, nasal opacification, nasal congestion, sense of smell, and HRQoL. In the subgroups with comorbid asthma (n ¼ 276 [58%] and n ¼ 448 [60%], 2 phase 3 studies), dupilumab significantly improved lung function and asthma control. 23, 24 This post hoc analysis of the phase 3 LIBERTY ASTHMA QUEST study 17 assessed the effect of dupilumab on severe exacerbations, lung function, patient-reported outcomes (PROs), and type 2 biomarkers in patients with moderate-to-severe asthma with and without comorbid CRS.
METHODS

Study design
LIBERTY ASTHMA QUEST (NCT02414854) is a previously reported, phase 3, randomized, double-blinded, placebo-controlled study assessing the effect of dupilumab in patients with uncontrolled, moderate-to-severe asthma. 17 The study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonization Good Clinical Practice guidelines, and applicable regulatory requirements. An independent data and safety monitoring committee conducted blinded monitoring of patient safety data, and an institutional review board or ethics committee at each study center oversaw trial conduct and documentation. All patients provided written informed consent before participating in the trial.
Study population
Complete inclusion and exclusion criteria are provided in this article's Online Repository at www.jaci-inpractice.org. 17 This post hoc analysis reports data for the subgroup of patients with CRS, defined as patients with self-reported comorbid CRS with or without NP as recorded in an e-diary at baseline. Patients not meeting these criteria were defined as non-CRS. Data were also analyzed in subgroups of patients with baseline blood eosinophils !150 cells/mL or !300 cells/mL, and baseline FeNO !25 ppb.
Study endpoints
Efficacy endpoints were the annualized severe asthma exacerbation rate and change from baseline in pre-and post-bronchodilator forced expiratory volume in 1 second (FEV 1 ). In addition, PROs were assessed during the 52-week treatment period using the scores from 3 patient-reported questionnaires: the 5-item Asthma Control Questionnaire (ACQ-5), Asthma Quality of Life Questionnaire (standardized version) (AQLQ[S]), and 22-item Sino-Nasal Outcome Test . The ACQ-5 is a measure of the level of asthma control (global score 0-6, with higher scores indicating less control), and the AQLQ(S) assesses the impact of asthma on HRQoL (global score 0-7, with higher scores indicating better HRQoL). The SNOT-22, administered only to patients selfreporting CRS, measures the impact of sino-nasal disorders on HRQoL (total score 0-110, with higher scores indicating greater HRQoL impairment). Within-patient improvement in ACQ-5, AQLQ(S), and SNOT-22 scores of at least 0.5, 0.5, and 8.9, respectively, were considered clinically meaningful as defined by the questionnaire developers. [25] [26] [27] [28] Concentrations of the following biomarkers of type 2 inflammation were also measured over the 52week treatment period in all patients: FeNO, serum total IgE, serum thymus and activation-regulated chemokines (TARCs), and peripheral blood eosinophils. Specific IgE for the following aeroantigens was assessed at baseline: Aspergillus fumigatus, cat dander, mite Dermatophagoides farinae, mite Dermatophagoides pteronyssinus, dog dander, German cockroach, Oriental cockroach, Alternaria tenuis/alternata, and Cladosporium herbarum/Hormodendrum.
Treatment-emergent adverse events (TEAEs) were reported for the CRS and non-CRS subgroups, and safety data were analyzed according to the treatment received.
Statistical analysis
Efficacy analyses were performed in the intention-to-treat (ITT) population, defined as all patients who underwent randomization, with data analyzed according to the assigned intervention. 19 Within each subgroup, annualized rates of severe exacerbations were derived from negative binomial regression models, which included the total number of events that occurred in the double-blind treatment period (regardless of whether the patient was on treatment) as the response variable. Covariates in the models included treatment group, age, baseline blood eosinophil level, baseline ICS dose level, geographic region, and number of severe exacerbations in the preceding year. Changes from baseline in pre-and post-bronchodilator FEV 1 , ACQ-5, AQLQ(S), and SNOT-22 scores were analyzed in each subgroup using mixed-effects models with repeated measures, with age, geographic region, baseline eosinophil level, baseline ICS dose level, visit, treatment-by-visit interaction, baseline level of the corresponding variable, and baseline-by-visit interaction as covariates. Baseline height and sex were also included as covariates in analyses of change from baseline in FEV 1 . Changes from baseline in type 2 inflammatory biomarkers in the exposed population, defined as all patients exposed to study medication, were summarized by descriptive statistics and compared based on a rank analysis of the covariance model adjusted for the baseline biomarker level, age, sex, geographic region, baseline eosinophil level, and baseline ICS dose level. A nominal P value of <.05 for the comparison between each dupilumab dose and matched-volume placebo (within each subgroup) was considered statistically significant.
RESULTS
Baseline characteristics
Of 1902 patients with uncontrolled, moderate-to-severe asthma in the ITT population, 382 (20.1%) self-reported comorbid CRS.
The baseline patient demographic and clinical characteristics of the CRS and non-CRS subgroups are shown in Table I 12] non-CRS, P ¼ .03) and had significantly higher levels of the type 2 biomarkers, FeNO, and peripheral blood eosinophils (both P < .0001), than those in the non-CRS subgroup. Baseline total IgE levels were similar between subgroups, with a smaller proportion of patients positive for !1 specific IgE in the CRS subgroup than in the non-CRS subgroup (P < .0001). In general, other baseline demographic and clinical characteristics were similar between the 2 subgroups. 
Annualized rate of severe asthma exacerbations
Dupilumab 200 mg or 300 mg administered every 2 weeks (q2w) significantly reduced annualized rates of severe asthma exacerbations compared with a matched-volume placebo (1.14 mL or 2.0 mL, respectively) in patients with and without CRS ( Figure 1, A) , with overall reductions of 63% (200 mg q2w) and 61% (300 mg q2w) in the CRS subgroup (both P < .001), and 42% (200 mg q2w) and 40% (300 mg q2w) in the non-CRS subgroup (both P < .001). In placebo-treated patients, the CRS subgroup had numerically higher adjusted annualized rates of severe asthma exacerbations than the non-CRS subgroup: for 1.14 and 2.0 mL q2w, the CRS subgroup had rates (95% confidence interval [CI]) of 1.25 (0.85-1.82) and 1.25 (0.88-1.78), compared with the non-CRS subgroup's rates of 0.79 (0.64-0.97) and 0.89 (0.72-1.10).
In general, dupilumab 200 and 300 mg q2w versus a matched-volume placebo showed a numerically greater reduction in severe exacerbation rate in the CRS subgroup than in the non-CRS subgroup in patients with baseline blood eosinophils !150 cells/mL (Figure 1 , B) and !300 cells/mL (Figure 1 , C), and in those with baseline FeNO !25 ppb (Figure 1 , D).
Pre-bronchodilator FEV 1
Dupilumab 200 and 300 mg q2w treatment resulted in rapid and sustained improvements in pre-bronchodilator FEV 1 versus a matched-volume placebo in both the CRS and non-CRS subgroups (Figure 2 , A, and Table E1 , available in this article's Online Repository at www.jaci-inpractice.org). In the CRS subgroup, dupilumab 200 and 300 mg q2w significantly improved prebronchodilator FEV 1 at week 2 with a least-squares (LS) mean change from baseline difference (95% CI) versus placebo of 0.20 L (0.10-0.31, P ¼ .0001) and 0.21 L (0.11-0.31, P < .0001), respectively; at week 12, 0.18 L (0.06-0. In both the CRS and non-CRS subgroups, treatment effects with 300 mg dupilumab versus a matched-volume placebo on change from baseline in pre-bronchodilator FEV 1 at week 12 were numerically greater in patients with baseline blood eosinophils !300 cells/mL and with baseline FeNO !25 ppb (Figure 2 , B).
Post-bronchodilator FEV 1
Dupilumab resulted in rapid and sustained improvements in post-bronchodilator FEV 1 versus a matched-volume placebo in both the CRS and non-CRS subgroups (Figure 3 , A, and Table E2 , available in this article's Online Repository at www.jaci-inpractice. org). In the CRS subgroup, dupilumab significantly improved post-bronchodilator FEV 1 by week 2 with an LS mean change from baseline difference (95% CI) versus placebo of 0.20 L (0.09-0.30, P ¼ .0002) and 0.21 L (0.11-0.31, P < .0001) for dupilumab 200 and 300 mg q2w, respectively. These improvements Week 52  48  44  40  36  32  28  24  20  16  12  10  8  6 In both the CRS and non-CRS subgroups, treatment effects on post-bronchodilator FEV 1 at week 12 were numerically greater in patients with baseline blood eosinophils !300 cells/mL and with baseline FeNO !25 ppb (Figure 3, B) .
ACQ-5 score
Dupilumab 200 and 300 mg q2w versus a matched-volume placebo improved asthma control as assessed by ACQ-5 scores in the CRS and non-CRS subgroups during the treatment period (P < .05, most comparisons) (Figure 4 , A, and For both dupilumab regimens, the change in ACQ-5 scores from baseline to week 52 in patients with asthma with CRS exceeded the clinically meaningful difference of 0.5 for this measure. 25, 26 The observed effects of dupilumab on ACQ-5 scores at week 52 were numerically greater in the CRS subgroup than in the non-CRS subgroup.
AQLQ(S) score
In general, both dupilumab regimens significantly (P < .05, most comparisons) improved HRQoL as assessed by AQLQ(S) scores versus a matched-volume placebo in the CRS and non-CRS subgroups during the treatment period (Figure 4 , B, and For both dupilumab regimens, the change in AQLQ(S) scores from baseline to week 52 in patients with asthma with CRS exceeded the clinically meaningful difference of 0.5 for this measure. 27 The observed effect of dupilumab on AQLQ(S) score at week 52 was numerically greater in the CRS subgroup than in the non-CRS subgroup.
SNOT-22 score
Patients treated with dupilumab versus placebo had significant improvement in CRS-specific symptoms and HRQoL as assessed by SNOT-22 scores during the treatment period (P < .05, all comparisons) (Figure 4 , C, and Week 36 52 Change from baseline in AQLQ global score, LS mean (± SE)
1.8 186  374  190  383   10 12  16  20  24  28  32  36  40  44 The magnitude of change in SNOT-22 scores from baseline to week 52 in dupilumab-treated patients exceeded 8.9, the difference regarded as clinically meaningful for this measure. 28 
Number of patients
Type 2 biomarkers
Rapid and sustained suppression of airway (FeNO) and systemic (total IgE, TARC) type 2 inflammatory biomarkers were observed in all dupilumab-treated patients. In both CRS and non-CRS subgroups, the change from baseline in FeNO levels with either dupilumab q2w dose regimen was significantly greater than in placebo-treated patients, in whom no change in FeNO was observed. These changes were evident by week 2 and Week 0 sustained over the 52-week study period (P < .01 all comparisons; Figure 5 , A, and Table E6 , available in this article's Online Repository at www.jaci-inpractice.org). For IgE and TARC ( Figure 5 , B and C, and Tables E7 and E8, available in this article's Online Repository at www.jaciinpractice.org), significant differences in reductions from baseline versus placebo were observed in both subgroups by week 12, with these differences evident throughout the 52-week treatment period (P < .01 for all IgE and TARC comparisons). No changes in serum total IgE or TARC were observed in placebo-treated patients.
No changes from baseline in blood eosinophil levels were observed throughout the study in non-CRS patients irrespective of treatment, whereas mild elevations were observed in CRS patients treated with dupilumab ( Figure 5 , D, and Table E9 , available in this article's Online Repository at www.jaciinpractice.org).
Safety
Rates of TEAEs were similar across treatment groups (placebo 83.1%; dupilumab 81.0%) in the overall population, as reported previously. 19 Injection-site reactions (Medical Dictionary for Regulatory Activities [MedDRA] High Level Term [HLT]) were the most frequent TEAEs, occurring at higher rates in dupilumab-treated patients than in placebo-treated patients (dupilumab 16.8%; placebo 7.9%). 19 In the CRS subgroup, serious TEAEs occurred in 12.8% of patients who received a placebo and in 7.2% of patients treated with dupilumab; in the non-CRS subgroup, the proportion of patients with serious TEAEs was similar in both treatment groups (7.2% placebo vs 8.5% dupilumab). Injection-site reactions (MedDRA HLT) occurred more frequently in dupilumab-treated patients (dupilumab vs placebo, 22.1% vs 10.5% and 15.5% vs 7.2% in the CRS and non-CRS subgroups, respectively) (Table II) .
In this analysis, the incidence of TEAEs was higher in the CRS subgroup (placebo 89.5%; dupilumab 83.5%) than in the non-CRS subgroup (placebo 81.4%; dupilumab 80.4%). In both subgroups, irrespective of treatment, viral upper respiratory tract infections were the most frequently reported TEAE (MedDRA Preferred Term) (Table III) .
DISCUSSION
This post hoc analysis of the LIBERTY ASTHMA QUEST study demonstrated that dupilumab treatment significantly reduced severe asthma exacerbations and improved pre-and post-bronchodilator FEV 1 in patients with moderate-to-severe asthma with and without comorbid CRS, with apparently greater improvements observed in the subgroups of patients with elevated baseline blood eosinophils and FeNO. Dupilumab improved patient-reported asthma control and HRQoL and suppressed type 2 inflammatory biomarkers in both subgroups. It also improved sino-nasal symptoms and HRQoL, as assessed by SNOT-22, in patients with CRS. The results obtained for the 2 subgroups of patients were consistent with the overall study results reported for the ITT population. 17 Patients with asthma with CRS are difficult to treat and have more severe disease. 2, 3 This was reflected by their significantly greater severe exacerbation history, and significantly higher levels of the type 2 inflammatory biomarkers, FeNO, and blood eosinophils, at baseline than those without CRS. These observations are consistent with previously published observations of increased expression of inflammatory biomarkers found in nasal polyp tissue of patients with CRS. 29 Consistent with its mechanism of action, dupilumab treatment provided rapid and sustained suppression of both local and systemic type 2 inflammatory biomarkers. At week 52 in both subgroups, the median FeNO levels in dupilumab-treated patients were consistent with previously reported FeNO levels for healthy patients ( 25 ppb). 30 A transient increase in mean peripheral blood eosinophils was observed in the overall ITT population, and it declined to baseline levels during treatment. 17 However, in this analysis, patients with CRS had higher median blood eosinophil levels at baseline and throughout the treatment period than patients without CRS, consistent with a type 2 inflammatory phenotype.
Interestingly, with dupilumab treatment, the magnitude of reductions in severe asthma exacerbations and improvement in FEV 1 from baseline was greater in the CRS subgroup than the non-CRS subgroup. This greater reduction may be due to the simultaneous symptom control of type 2-mediated inflammation of both upper and lower airways by dupilumab, leading to improvements in both CRS (upper airway) and asthma (lower airway) outcome measures. Recent studies have demonstrated that targeting the IL-5 pathway may be efficacious in the treatment of asthma in a subgroup of patients with severe eosinophilic asthma with comorbid CRS. [31] [32] [33] The numerical difference in efficacy between the CRS and non-CRS groups could also result from between-group differences in baseline characteristics such as exacerbation rate and type 2 biomarkers. It is also noteworthy that dupilumab resulted in a numerically greater reduction in severe exacerbations in the subgroup with CRS, given that this subgroup had a higher severe exacerbation rate and type 2 burden at baseline compared with the non-CRS subgroup.
The findings reported here support and extend the data obtained from a previously published proof-of-concept, phase 2, randomized, placebo-controlled study of dupilumab in patients with CRS and NP. 22 Adding dupilumab 300 mg q2w to intranasal corticosteroid therapy significantly reduced the burden of NP while improving FEV 1 and asthma control, as well as sense of smell, sinus computed tomography scans, and quality of life in patients with CRS, NP, and comorbid asthma. Phase 3 studies of dupilumab in CRS and NP have recently been completed, confirming and extending these positive results. 23, 24 Consistent with safety in the overall population of the QUEST phase 3 study, 17 dupilumab had an acceptable safety profile in patients with and without CRS and was generally well tolerated. Injection-site reactions occurred more frequently in dupilumab-treated patients than in placebo-treated patients, being more frequent in patients with CRS than in those without CRS.
A major limitation of this analysis is that the diagnosis of CRS was based on patient self-reporting rather than clinician diagnosis. Patients with past but no current symptoms of CRS may not have reported themselves as having CRS and therefore may have been included in the non-CRS group. In addition, we were unable to evaluate any differences in outcomes between CRS with and without NP, as this level of data was not obtained. Nonetheless, the significant baseline differences between the subgroups with and without a diagnosis of CRS (older age, more asthma exacerbations in the previous year, higher levels of type 2 biomarkers, smaller proportion positive for !1 specific IgE) suggest that patient self-reporting identified a specific phenotype. Recent evidence indicates that type 2 inflammation is present in patients with CRS with and without NP. 9 Although our study was not specifically designed to compare patients with and without CRS, the power was sufficient for a careful and rigorous evaluation of asthma clinical outcomes, biomarkers, and PROs in this population with comorbid disease. In addition, studies of reslizumab and benralizumab in patients with asthma also relied on self-reporting to identify patients with CRS with or without NP. 33, 34 This post hoc analysis suggests that adding dupilumab 200 or 300 mg q2w to medium-to-high-dose ICS plus long-acting b 2 -agonist therapy was effective and well tolerated in patients with uncontrolled, moderate-to-severe asthma with and without comorbid CRS. Improvements in asthma control occurred rapidly and were sustained over the 52-week study period. Notably, the clinical benefits associated with dupilumab in terms of efficacy and improved quality of life were particularly evident in the subgroup of patients with comorbid asthma and CRS. These patients represent a difficult-to-treat subpopulation of patients with asthma, with high levels of inflammatory biomarkers and baseline disease burden, and increased risk of asthma exacerbations. Dupilumab was particularly efficacious in these patients, providing evidence of improving symptoms in comorbidities of both the upper and lower airways. ANCOVA, Analysis of covariance; CI, confidence interval; CRS, chronic rhinosinusitis; ICS, inhaled corticosteroid; q2w, every 2 weeks. P values are comparing dupilumab vs matched placebo for change in blood eosinophil count from baseline and are based on the rank ANCOVA model adjusted for baseline blood eosinophil count, age, sex, geographic region, baseline eosinophil strata, and baseline ICS dose level.
